Neuren Pharmaceuticals Stock

Detail Data
Volume (24h): 570,076 shares
P/E Ratio: 11.25
Forward P/E: 21.14
EPS: 1.09 AUD
Forward EPS: 0.58 AUD
Number of Shares: 126,339,000 shares
Market Capitalization: 1,548,916,224.00 AUD

Dividend

Dividend Value
Dividend Amount According to our data, the company Neuren Pharmaceuticals does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a strong_buy recommendation for Neuren Pharmaceuticals stock. The current number of analysts covering this company is 8. The highest target price is 30.8 AUD, while the lowest target price is 18.6 AUD. The median target valuation set by analysts is 24.75 AUD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Neuren Pharmaceuticals.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Neuren Pharmaceuticals stock is: strong_buy
Number of Analysts: 8
Highest Target Price: 30.8 AUD
Lowest Target Price: 18.6 AUD
Median Target Price: 24.75 AUD

Fundamental Indicators

Indicator Data
Total Revenue: 216,832,000.00 AUD
Net Income: 142,043,008.00 AUD
Price-to-Book (P/B): 4.28
PEG Ratio: /
Exchange: ASX
Industry: Biotechnology
Sector: Healthcare
Number of Employees:
Country: Australia

Where to Buy Neuren Pharmaceuticals Stock?

You can purchase Neuren Pharmaceuticals stock on the ASX under the ticker symbol: NEU.AX. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Neuren Pharmaceuticals Stock

Indicator Value
Company Revenue: 216,832,000.00 AUD
EBITDA: 179,183,008.00 AUD - Positive EBITDA indicates profitable operations before interest, taxes, depreciation, and amortization.
Earnings Per Share: 1.09 AUD
Book Value Per Share: 2.87 AUD
Total Cash: 222,242,000.00 AUD
Total Cash per Share: 1.75 AUD
Total Debt: -
Debt to Equity Ratio: -
Quick Ratio 8.69
Current Ratio 8.73
Free Cash Flow -42,251,376.00 AUD
Operating Cash Flow -11,270,000.00 AUD
Gross Margins 84.80 %
EBITDA Margins 82.64 %
Operating Margins 90.96 %
Profit Margins 65.51 %
Return on Assets 34.1 %
Return on Equity 49.9 %
Earnings Growth (1 year) 23.3%
Revenue Growth (1 year) 13.9 %
Quarterly Earnings Year-over-Year Growth 22.6 %
Market Capitalization 1,548,916,224.00 AUD
Enterprise Value 1,370,496,256.00 AUD
EV/Revenue 6.321
EV/EBITDA 7.649
Float Shares 110,356,188 shares
Shares Outstanding 126,339,000 shares
Held Percent Insiders 0.13 %
Held Percent Institutions 20.49 %
Shares Short -
Shares Short Prior Month -
Date Short Interest -
Short Percentage of Total Shares -
Short Ratio -
Beta 1.73
Short Percentage of Float -
Implied Shares Outstanding 127,155,000

Frequently Asked Questions (FAQ)

According to our data, the company Neuren Pharmaceuticals does not pay dividends yet, even in 2025.

Neuren Pharmaceuticals shares are traded on the ASX stock exchange under the ticker: NEU.AX. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Neuren Pharmaceuticals shares is from a total of 8 analysts. The average target price prediction is 24.75 AUD per share.

The total number of Neuren Pharmaceuticals shares on the exchange is 126,339,000.00 shares, which at the current market capitalization gives the company a total valuation of 1,548,916,224.00 AUD.